Based on a number of laboratory data and clinical evidence, TNF-α inhibitors were implied as new therapeutic strategies in several immune-related diseases, including rheumatoid arthritis, asthma, sarcoidosis, inflammatory bowel disease, pancreatitis, and so on [73–75]. This evidence concerns the gene TNF and rheumatoid arthritis.